| Identification | Back Directory | [Name]
Ladiratuzumab | [CAS]
1629760-28-6 | [Synonyms]
Ladiratuzumab
Research Grade Ladiratuzumab
Ladiratuzumab (anti-SLC39A6)
Research Grade Ladiratuzumab (DHG52901) |
| Hazard Information | Back Directory | [Uses]
Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC)[1][2]. | [References]
[1] Trail PA, et al. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. Pharmacol Ther. 2018 Jan;181:126-142. DOI:10.1016/j.pharmthera.2017.07.013
[2] Cao, et al. Additional mechanisms of action of ladiratuzumab vedotin contribute to increased immune cell activation within the tumor. Cancer Research 78.13_Supplement (2018): 2742-2742. |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|